Furthermore, a recent meta-analysis indicated that evaluating NT-proBNP can aid physicians to discriminate COVID-19 patients at high risk.14 However, another meta-analysis, reported by Dawson et al., has not reported a significant dissimilarities in NT-proBNP levels between the patients who died or were critically ill with those who survived or were not critically ill.5 The main reason of the similarity of NT-proBNP levels in both groups in this meta-analysis was possibly due to the inclusion of patients with pre-existing HF. This evidence concerns the gene NPPB and COVID-19.